These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Management of complicated urinary tract infections in the era of antimicrobial resistance. Bader MS; Hawboldt J; Brooks A Postgrad Med; 2010 Nov; 122(6):7-15. PubMed ID: 21084776 [TBL] [Abstract][Full Text] [Related]
46. Suboptimal aminoglycoside dosing in critically ill patients. Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371 [TBL] [Abstract][Full Text] [Related]
47. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Niederman MS Clin Infect Dis; 2006 Jan; 42 Suppl 2():S72-81. PubMed ID: 16355320 [TBL] [Abstract][Full Text] [Related]
48. Optimal use of fluoroquinolones in the intensive care unit setting. Rotschafer JC; Ullman MA; Sullivan CJ Crit Care Clin; 2011 Jan; 27(1):95-106. PubMed ID: 21144988 [TBL] [Abstract][Full Text] [Related]
49. Empiric antibiotic selection strategies for healthcare-associated pneumonia, intra-abdominal infections, and catheter-associated bacteremia. Snydman DR J Hosp Med; 2012; 7 Suppl 1():S2-S12. PubMed ID: 23737334 [TBL] [Abstract][Full Text] [Related]
50. Empiric antibiotic selection strategies for healthcare-associated pneumonia, intra-abdominal infections, and catheter-associated bacteremia. Snydman DR J Hosp Med; 2012; 7 Suppl 1():S2-12. PubMed ID: 23677631 [TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. Lipš M; Siller M; Strojil J; Urbánek K; Balík M; Suchánková H Int J Antimicrob Agents; 2014 Oct; 44(4):358-62. PubMed ID: 25216543 [TBL] [Abstract][Full Text] [Related]
52. Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit. Xu Y; Jin L; Liu N; Luo X; Dong D; Tang J; Wang Y; You Y; Liu Y; Chen M; Yu Z; Hao Y; Gu Q Int J Infect Dis; 2019 May; 82():79-85. PubMed ID: 30878630 [TBL] [Abstract][Full Text] [Related]
57. Probiotics in the intensive care unit. Morrow LE; Gogineni V; Malesker MA Nutr Clin Pract; 2012 Apr; 27(2):235-41. PubMed ID: 22473797 [TBL] [Abstract][Full Text] [Related]
58. Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter? Cooper TW; Pass SE; Brouse SD; Hall RG Ann Pharmacother; 2011 Feb; 45(2):229-40. PubMed ID: 21304038 [TBL] [Abstract][Full Text] [Related]
59. Antibiotic dosing for multidrug-resistant pathogen pneumonia. Abdul-Aziz MH; Lipman J; Roberts JA Curr Opin Infect Dis; 2017 Apr; 30(2):231-239. PubMed ID: 28030371 [TBL] [Abstract][Full Text] [Related]
60. In vitro bacterial isolate susceptibility to empirically selected antimicrobials in 111 dogs with bacterial pneumonia. Proulx A; Hume DZ; Drobatz KJ; Reineke EL J Vet Emerg Crit Care (San Antonio); 2014; 24(2):194-200. PubMed ID: 24382329 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]